Mexico's Journey to Tobacco Control: Overcoming Industry Resistance.

Dec.07.2022
Mexico's Journey to Tobacco Control: Overcoming Industry Resistance.
Mexico approved the WHO Framework Convention on Tobacco Control in 2004, but it took 20 years for it to be incorporated into law.

In 2004, Mexico became the first country in the Americas to approve the groundbreaking World Health Organization Framework Convention on Tobacco Control. However, it took another 20 years for its measures to be incorporated into Mexican law. "When faced with one of the world's largest and most powerful industries, patience, perseverance, and cooperation are the only way forward," said Dr. Juan Arturo Sabines, National Tobacco Advisor for the Pan-American Health Organization (PAHO).


Tobacco use is the most preventable cause of death in the world today. Nearly one million people die every year in the Americas alone from direct consumption or exposure to secondhand smoke. It accounts for 15% of deaths from cardiovascular disease, 24% of cancer deaths, and 45% of deaths from chronic respiratory disease.


The opposition to tobacco began in the 1950s, when the medical community started gathering evidence of smoking's link to serious diseases, particularly cancer," said Adriana Bacelar Gomes, a tobacco control expert at the Pan American Health Organization. "That was the first initiative to begin restricting the industry and standardizing tobacco products and their use, and when our work began.


However, 60 years later, tobacco remains the only legal consumer product that causes up to half of its users to die.


In the past 20 years, the Pan-American Health Organization has focused on supporting countries in their efforts to adopt and implement the World Health Organization Framework Convention on Tobacco Control (WHO FCTC). This legally binding international treaty is designed to promote cost-effective measures to control tobacco use, including preventing secondhand smoke in all indoor workplaces and public places, large graphic health warnings on tobacco product packaging, comprehensive bans on tobacco advertising, promotion, and sponsorship, and increasing tobacco product taxes.


Although these measures make a lot of sense in terms of protecting public health and reducing the strain on the healthcare system, strong industry resistance has caused delays in their implementation, often spanning several years.


In tobacco control, there is a very powerful and resourceful industry that directly opposes public health efforts. They are prepared to use everything in their arsenal to prevent a decrease in demand for their products, which is a critical public health goal," said Bacelar Gomes.


Regarding Mexico, the first tangible action taken after the approval of the World Health Organization's Framework Convention on Tobacco Control was the enactment of the General Tobacco Control Law in 2008.


The law has adopted measures from the WHO FCTC, but only partially," said Sabines. "For example, although it proposes smoke-free public places, it still allows people to smoke in designated indoor areas, which fails to protect the public from secondhand smoke.


The efforts of the Pan American Health Organization over the next 13 years will be crucial in amending laws. This includes ongoing technical support for the Mexican Ministry of Health, building capacity, developing and disseminating scientific evidence to support these measures, and public awareness campaigns to educate the public about the dangers of tobacco use.


Lately, technological collaborations have included efforts to help prevent young people from using new products such as e-cigarettes and heated tobacco products, which are actively marketed as "healthier alternatives".


During the period of legal revision from 2008 to 2021, Congress proposed over 100 initiatives to update tobacco control laws. "These measures included improvements to packaging and advertising legislation, as well as initiatives to create smoke-free areas in public places," Sabines stated. However, none of them were implemented.


During this time, the Pan-American Health Organization's national office organized meetings with domestic and international partners, technical experts, and health ministry officials to develop a strategy for advancing the country's tobacco control law amendment. This included collaborating with national media outlets to publish articles and editorials highlighting the importance of tobacco control.


The COVID-19 pandemic has increased the urgency for tobacco control.


Once the pandemic began, the link between tobacco consumption and non-communicable diseases could no longer be ignored. COVID-19 has caused thousands of deaths in the Americas, and those with preexisting conditions, particularly chronic respiratory diseases and other diseases caused by smoking, have been especially affected.


Although it has been challenging during the pandemic to focus on public health issues other than COVID-19, the importance of implementing strict public health policies to protect people from unhealthy products such as tobacco has become immediately evident," said Luciana Severini, an international advisor for the Pan American Health Organization, regarding tobacco control.


The Mexican Senate has unanimously approved a tobacco control bill amendment that establishes 100% smoke-free environments and completely bans advertising, promotion, and sponsorship. This comes as a result of the tireless efforts of the Pan American Health Organization and the tobacco control industry. The new law takes effect on December 14, 2021.


This amendment represents a historic step forward for Mexico in its anti-smoking policies, and reaffirms its role as one of the leaders in the global fight against tobacco," said Christian Morales, former representative of the Pan American Health Organization/World Health Organization in Mexico.


Although Mexico is one of the countries in the region that has successfully implemented laws to protect people from the harmful effects of tobacco use, there is still much work to be done to reduce the risk factors for non-communicable diseases such as smoking in the Americas.


The Pan-American Health Organization is continuing to work with member countries to address non-communicable diseases. This is being achieved through the implementation of policies and legislation, the provision of management guidelines, monitoring and surveillance, capacity building and public awareness campaigns.


2FIRSTS will continue to follow and report on this topic. Further updates will be available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York State will extend its tobacco products tax to “alternative nicotine products,” including tobacco-free nicotine pouches, from September 1, 2026, at a rate of 75% of the wholesale price. Distributors, wholesalers and retailers must also inventory products held as of 11:59 p.m. on August 31 and pay a floor tax. Vapor products are excluded from the new category and remain subject to New York's separate 20% supplemental sales tax on the retail price.
Aug.26
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13